Baird analyst David Rescott initiated coverage of Inari Medical with an Outperform rating and $79 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical to Announce Second Quarter 2023 Financial Results
- Penumbra price target raised to $376 from $325 at Deutsche Bank
- Inari Medical Announces the Release of 2022 Ethos and Sustainability Report
- Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients